MeiraGTx, a London and New York-based gene therapy company, today announced that the Offices of Orphan Products Development and Pediatric Therapeutics of the U.S. Food and Drug Administration (FDA) have granted rare pediatric disease designation to the Company’s gene therapy product candidate AAV2/5-OPTIRPE65 (A001) for the treatment of patients with Leber’s Congenital Amaurosis due to mutations in the RPE65 gene (LCA2)